Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: A case- controlled study on eighty-four patients

European Journal of Dermatology

Volumn 23, Issue 3, 2013, Pages 350-355

  Elela, Mostafa Abou ^a   Hegazy, Rehab A ^a   Fawzy, Marwa Mohamed ^a   Rashed, Lalia A ^a   Rasheed, Hoda ^a  

^a Cairo University   (Egypt)

Author keywords

FoxP3; IL 17; IL 22; T regs; Th 17; Vitiligo

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SKIN BIOPSY; STRESS SCORE; TH17 CELL; TISSUE LEVEL; VITILIGO; VITILIGO AREA SCORING INDEX; VITILIGO DISEASE ACTIVITY; ADOLESCENT; BIOSYNTHESIS; BLOOD; CHEMISTRY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SKIN; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MALE; MIDDLE AGED; SKIN; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; VITILIGO; YOUNG ADULT;

EID: 84880629718     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2023     Document Type: Article

References (35)

1. Manuel S-C, Mario G-C, Reňi{dotless}an Ši{dotless}-P, et al. Immunopathogenesis of Vitiligo. Autoimmunity Rev 2011; 1016: 30-9.
2. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006; 24: 677-88.
3. Mai J, Wang H, Yang XF. Th 17 cells interplay with Foxp3+ Tregs in regulation of inflammation and autoimmunity. Front Biosci 2010; 15: 986-1006, Review.
4. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9.
5. Dummer CD, Carpio VN, Gonçalves LF, et al. FOXP3+ regulatory T cells: from suppression of rejection to induction of renal allograft tolerance. Transpl Immunol 2012; 26: 1-10.
6. Njoo M, Das P, Bos J, et al. Association of the kobner phenomenon with disease activity and therapeutic responsiveness in vitiligo vulgaris. Arch Dermatol 1999; 135: 407.
7. Roberti J, Harrington L, Storch E. Further psychometric support for the 10-Item version of the perceived stress scale. J Univ Counsel 2006; 9: 135-47.
8. Kawakami T, Hashimoto T. Disease severity indexes and treatment evaluation criteria in vitiligo. Dermatol Res Pract 2011; 2011: 750342.
9. El Mofty M, Ramadan S, Fawzy MM, et al. Broad band UVA: a possible reliable alternative to PUVA in the treatment of early-stage mycosis fungoides. Photodermatol Photoimmunol Photomed. 2012; 28: 274-7.
10. Burl S, Hill PC, Jeffries DJ, et al. FOXP3 gene expression in a tuberculosis case contact study. Clin Exp Immunol 2007; 149: 117-22.
11. Pan F, Fan H, Lu L, et al. The yin and yang of signaling in T-regs and TH17 cells. Sci Signal 2011; 4: mr4.
12. Abdulahad WH, Boots AM, Kallenberg CG. FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells. Rheumatol 2011; 50: 646-56.
13. Basak PY, Adiloglu AK, Ceyhan AM, et al. The role of helper and regulatory T cells in the pathogenesis of vitiligo. J Am Acad Dermatol 2009; 60: 256-60.
14. Bassiouny DA, Shaker O. Role of interleukin-17 in the pathogenesis of vitiligo. Clin Exp Dermatol 2010; 36: 292-7.
15. Wang CQ, Cruz-Inigo AE, Fuentes-Duculan J, et al. Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One 2011; 6: e18907.
16. Ting-huil LI, Xiao-bin HOU, Xiao Li H., et al. Role of CD4+ CD25+ regulatory T cells & Foxp3 expression in pathogenesis of vitiligo. Chin J Aesth Med 2009; 6: 819-22.
17. Klarquist J, Denman CJ, Hernandez C, et al. Reduced skin homing by functional T-reg in vitiligo. Pigment Cell Melanoma Res 2010; 23: 276-86.
18. Lili Y, Yi W, Ji Y, Yue S, Weimin S, Ming L. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PLoS One 2012; 7: e37513.
19. Zhou L, Li K, Shi YL, et al. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. Pigment Cell Melanoma Res 2012; 25: 602-11.
20. Tran DQ. TGF-_: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 2012; 4: 29-37, Review.
21. Stockinger B, Veldhoen M, Martin B. Th17 T cells: linking innate and adaptive immunity. Semin Immunol 2007; 19: 353-61, Review.
22. Tu CX, Jin WW, Lin M, et al. Levels of TGF-_(1) in serum and culture supernatants of CD4(+)CD25 (+) T cells from patients with nonsegmental vitiligo. Arch Dermatol Res 2011; 303: 685-9.
23. Nistala K, Wedderburn LR. Review Th17 and regulatory T cells: rebalancing pro-and anti-inflammatory forces in autoimmune arthritis. Rheumatol 2009; 48: 602-6.
24. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J. Immunol 2003; 170: 1304-12.
25. Afzali B, Lombardi G, Lechler RI, et al. The role of T helper 17 (Th17) and regulatory T cells (T-reg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148: 32-46.
26. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmune Rev 2007; 6: 169-75.
27. Heo YJ, Joo YB, Oh HJ, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunology Letters 2010; 127: 150-6.
28. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-76.
29. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-40.
30. Kotake S, Udagawa N, Takahashi N N. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-52.
31. Taieb A, Picardo M A. Clinical practice. Vitiligo. N Engl J Med 2009; 360: 160-9.
32. Musette P, Bachelez H, Flageul B, et al. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol 1999; 162: 1789-94.
33. Moretti S, Arunachalam M, Colucci R, et al. Autoimmune markers in vitiligo patients appear correlated with obsession and phobia. J Eur Acad Dermatol venereal 2012; 26: 861-7.
34. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98, Review.
35. Korn T, Bettelli E, Oukka M, et al. IL-17 and Th17 Cells. An Rev Immunol 2009; 27: 485-517.